Trainable immunohistochemical HER2/neu image analysis: A multisite performance study using 260 breast tissue specimens

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 7, 2011, Pages 896-902

  Nassar, Aziza ^a,i   Cohen, Cynthia ^a   Agersborg, Sally S ^b   Zhou, Weidong ^b   Lynch, Kathleen A ^b   Albitar, Maher ^b   Barker, Edward A ^c   Vanderbilt, Burton L ^d,h   Thompson, Jim ^e   Heyman, Eugene R ^f   Lange, Holger ^f   Olson, Allen ^f   Siddiqui, Momin T ^g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c Medical Laboratory Associates   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e Pathology Department   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g EMORY UNIVERSITY HOSPITAL   (United States)

^h Bartlett Regional Hospital   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST; BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MICROSCOPY;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 79960795310     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Powell WC, Hicks DC, Prescolt N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH) and interlaboratory reproducibility. Appl Immunohistochem MolMorphol. 2007; 15(1):94-102. (Pubitemid 46673324)
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. (Pubitemid 32222155)
3. Turashvili G, Leung S, Turbin D, et al. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer. 2009;9:165.
4. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1): 118-145. (Pubitemid 350003059)
5. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations [quiz in J Natl Compr Cane Netw. 2006;4(suppl 3):S23-S24]. J Natl Compr Cane Netw. 2006;4(suppl 3):S1-S22.
6. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissuebased detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18(21):3651-3664.
7. Persons DL, Bui MM, Lowery MC, et al. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci. 2000;30(1):41-48. (Pubitemid 30078303)
8. Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2006;48(6):702-707.
9. Laudadio J, Quigley DI, Tubbs R, Wolff DJ. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn. 2007;7(1):53-64. (Pubitemid 46114707)
10. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of Her-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002; 118(93):408-417. (Pubitemid 37046339)
11. Ciampa A, Xu B, Ayata G, et al. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol. 2006; 14(2):132-137. (Pubitemid 43941174)
12. Tawfik OW, Kimler BF, Davis M, et al. Comparison of immunohistochemistry by automated cellular imaging system (AGS) versus fluorescence insitu hybridization in the evaluation of HER2 expression in primary breast carcinoma. Histopathology. 2006;48 (3):258-267.
13. Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005;58(7):710-714. (Pubitemid 40956824)
14. Hatanaka Y, Hashizume K, Nitta K, Kato T, Itoh I, Tani Y. Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas. Pathol Int. 2003,53(10):693-699. (Pubitemid 37430936)
15. Joshi AS, Sharangpani GM, Porter K, et al. Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A. 2007;71(5):273-285. (Pubitemid 46717324)
16. Skaland I, Ovestad I, Janssen EA, et al. Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer..J Clin Pathol. 2008,61(1 ):68-71. (Pubitemid 351158228)
17. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. ; Clin Oncol. 2001;19(2):354-363. (Pubitemid 32112846)
18. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004; 121(5):620-630. 1 (Pubitemid 38533993)
19. Anderson JM, Ariga R, Govil H, et al. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. Appl Immunohistochem Mol Morphol. 2003; 11(2):120-124. (Pubitemid 36749563)
20. Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15(2):137-145. (Pubitemid 34171323)
21. Minot DM, Kipp BR, Root RM, et al. Automated cellular imaging system III for assessing HER2 status in breast cancer specimens-development of a standardized scoring method that correlates with FISH. Am J Clin Pathol. 2009; 132(1 ):133-138.
22. Liiftner D, Henschke P, Kafka A, et al. Discordant results obtained for different methods of HER-2/neu testing in breast cancer-a question of standardization, automation and timing. Int J Biol Markers. 2004;19(1):1-13. (Pubitemid 38515006)
23. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol. 2001;25(9):1208-1210.
24. Braunschweig T, Chung JY, Hewitt SM. Perspectives in tissue microarrays. Combinatorial Chem High Throughput Screening. 2004;7(6):575-585. (Pubitemid 39180742)
25. Braunschweig T, Chung |Y, Hewitt SM. Tissue microarrays: bridging the gap between research and the clinic. Expert Rev Proteomics. 2005;2(3):325-326.
26. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarray. Nature Med. 2002; 8(11):1323-1327. (Pubitemid 35373567)
27. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of Her2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Nat Cancer Inst. 2002,94(11):852-854. (Pubitemid 34705057)
28. van Diest PJ, van Dam P, Henzen-Logmans SC, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. Clin Pathol. 1997;50(10):801-804. (Pubitemid 27475783)